| Total 939 Paclitaxel
related US patents (from
US Patent & Trademark Office)
No. 1
- 100 / 101-200
/ 201 - 300 / 301
- 400 / 401 - 500
/ 501 - 600 / 601
- 700 / 701 - 800
/ 801
- 900 / 901 -939
/
No. 601 - 700 Paclitaxel Patents:
|
PAT. NO. |
|
Title |
| 601 |
6,153,193 |
 |
Compositions
for targeting biological agents |
| 602 |
6,150,537 |
|
Methods
for the esterification of alcohols and compounds useful therefor as
potential anticancer agents |
| 603 |
6,150,407 |
|
Methods
for inhibiting angiogenesis |
| 604 |
6,150,398 |
|
Methods
for the treatment of cancer |
| 605 |
6,147,107 |
|
Specific
inhibition of the P42/44 mitogen activated protein (map) kinase
cascade sensitizes tumor cells |
| 606 |
6,147,094 |
|
Reduction
of cardiotoxicity of an antitumor agent using manganese compound |
| 607 |
6,147,082 |
|
Chalcones
having antiproliferative activity |
| 608 |
6,147,076 |
|
Analogues
of N-acetylardeemin, method of preparation and uses thereof |
| 609 |
6,147,060 |
|
Treatment
of carcinomas using squalamine in combination with other anti-cancer
agents |
| 610 |
6,146,659 |
|
Method
of administering liposomal encapsulated taxane |
| 611 |
6,143,902 |
|
C-2
hydroxyl protected-N-acyl (2R,3S)-3-phenylisoserine N-imido
activated esters and method for production thereof |
| 612 |
6,143,321 |
|
Liposomes
containing active agents |
| 613 |
6,140,362 |
|
Method
for inhibiting the growth of mammalian cells |
| 614 |
6,140,359 |
|
Injectable
composition |
| 615 |
6,140,067 |
|
Indicators
of altered mitochondrial function in predictive methods for
determining risk of type 2 diabetes mellitus |
| 616 |
RE36,939 |
|
Composition
for therapy of diseases with ultrasonic and pharmaceutical liquid
composition containing the same |
| 617 |
6,136,999 |
|
C-2
hydroxyl protected-n-acyl (2R,3S)-3-phenylisoserine substituted
phenyl activated esters and method for production thereof |
| 618 |
6,136,990 |
|
Taxoid
compound and method for producing the same |
| 619 |
6,136,989 |
|
Method
for high yield and large scale extraction of paclitaxel from
paclitaxel-containing material |
| 620 |
6,136,988 |
|
7-hexanoyltaxol
and methods for preparing the same |
| 621 |
6,136,961 |
|
Biocatalytic
methods for synthesizing and identifying biologically active
compounds |
| 622 |
6,136,846 |
|
Formulation
for paclitaxel |
| 623 |
6,136,835 |
|
Methods
of treatment for viral infections |
| 624 |
6,133,462 |
|
C-7
CBZ baccatin III and production method therefor |
| 625 |
6,133,316 |
|
Use
of nitric oxide inhibitors for treating side effects of particulate
drugs |
| 626 |
6,132,765 |
|
Drug
delivery via therapeutic hydrogels |
| 627 |
6,132,722 |
|
Recombinant
antibody-enzyme fusion proteins |
| 628 |
6,130,336 |
|
Process
for preparing paclitaxel |
| 629 |
6,130,245 |
|
Dinuclear
platinum complexes as cisplatin analogs for cancer treatment |
| 630 |
6,130,219 |
|
Drug
resistance and multidrug resistance modulators |
| 631 |
6,130,200 |
|
Gel
composition and methods |
| 632 |
6,129,757 |
|
Implantable
members for receiving therapeutically useful compositions |
| 633 |
6,127,555 |
|
Taxane
hydroxy monoacylation method |
| 634 |
6,127,407 |
|
Withdrawn |
| 635 |
6,127,406 |
|
Discodermolide
compounds and methods of use |
| 636 |
6,127,390 |
|
Inhibitors
of prenyl-protein transferase |
| 637 |
6,127,355 |
|
High
molecular weight polymer-based prodrugs |
| 638 |
6,127,351 |
|
Method
for the administration of amifostine and related compounds |
| 639 |
6,126,933 |
|
Methods
of treating inflammatory bowel diseases by administering IL-11 |
| 640 |
6,124,482 |
|
Process
for isolation of 10-deacetyl baccatin-III |
| 641 |
6,124,311 |
|
Methods
for treating resistant tumors |
| 642 |
6,121,299 |
|
Modulating
inflammation with cytochrome P-450 activators and inhibitors |
| 643 |
6,121,292 |
|
Methods
for reversing multidrug resistance |
| 644 |
6,121,278 |
|
Di-n-heterocyclic
compounds, methods, and compositions for inhibiting parp activity |
| 645 |
6,121,252 |
|
Phosphinic
acid derivatives |
| 646 |
6,118,011 |
|
Preparation
of liposomal taxanes |
| 647 |
6,117,949 |
|
Biodegradable
low molecular weight triblock poly (lactide-co-glycolide)
polyethylene glycol copolymers having reverse thermal gelation
properties |
| 648 |
6,117,425 |
|
Supplemented
and unsupplemented tissue sealants, method of their production and
use |
| 649 |
6,114,376 |
|
Methods
for using macrocyclic lactone compounds as multidrug resistance
reversing agents in tumor and other cells |
| 650 |
6,114,160 |
|
Compositions
and methods for taxol biosynthesis |
| 651 |
6,113,906 |
 |
Water-soluble
non-antigenic polymer linkable to biologically active material |
| 652 |
6,110,953 |
|
Pharmaceutical
composition for inhibiting the growth of cancers |
| 653 |
6,110,891 |
|
Lectin
compositions and uses thereof |
| 654 |
6,107,497 |
|
Intermediate
for use in docetaxel synthesis and production method therefor |
| 655 |
6,107,333 |
|
Parenteral
paclitaxel in a stable non-toxic formulation |
| 656 |
6,107,332 |
|
Hydrolysis-promoting
hydrophobic taxane derivatives |
| 657 |
6,107,305 |
|
Use
of pyrazolo [3,4-b] pyridine as cyclin dependent kinase inhibitors |
| 658 |
6,107,034 |
|
GATA-3
expression in human breast carcinoma |
| 659 |
6,106,866 |
|
In
vivo agents comprising cationic drugs, peptides and metal chelators
with acidic saccharides and glycosaminoglycans, giving improved
site-selective localization, uptake mechanism, sensitivity and
kinetic-spatial profiles, including tumor sites |
| 660 |
6,103,698 |
|
Dolastatin-15
derivatives in combination with taxanes |
| 661 |
6,103,487 |
|
Method
of treating cancer |
| 662 |
6,100,411 |
|
Taxoid
anti-tumor agents and pharmaceutical compositions thereof |
| 663 |
6,099,563 |
|
Substrates,
particularly medical devices, provided with bio-active/biocompatible
coatings |
| 664 |
6,096,911 |
|
Process
for purifying alkoxylated fats |
| 665 |
6,096,909 |
|
Taxoid
anti-tumor agents and pharmaceutical compositions thereof |
| 666 |
6,096,757 |
|
Method
for treating proliferative diseases |
| 667 |
6,096,331 |
|
Methods
and compositions useful for administration of chemotherapeutic
agents |
| 668 |
6,096,303 |
|
Method
to enhance treatment of cystic tumors |
| 669 |
6,093,743 |
|
Therapeutic
methods employing disulfide derivatives of dithiocarbamates and
compositions useful therefor |
| 670 |
6,093,391 |
|
Peptide
copolymer compositions |
| 671 |
6,090,951 |
|
Methods
for the preparation of novel sidechain-bearing taxanes and
intermediates |
| 672 |
6,090,844 |
|
Pharmaceutical
injection solution containing taxol |
| 673 |
6,090,796 |
|
Pharmaceutical
composition for inhibiting the growth of cancers |
| 674 |
6,087,350 |
|
Use
of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| 675 |
6,080,877 |
|
Taxanes |
| 676 |
6,077,862 |
|
Virus
and cancer treatments |
| 677 |
6,077,499 |
|
Targeted
combination immunotherapy of cancer |
| 678 |
6,074,873 |
|
Nucleic
acids encoding NL-3 |
| 679 |
6,074,643 |
|
Site-directed
chemotherapy of metastases |
| 680 |
6,071,965 |
|
Phosphinic
alkanoic acid derivatives |
| 681 |
6,071,952 |
|
Stabilized
injectable pharmaceutical compositions containing taxoid anti-neoplastic
agents |
| 682 |
6,071,947 |
|
Indolyl-pyrrolydenemethylpyrrole
derivatives and process for their preparation |
| 683 |
6,071,930 |
|
Method
for treating tumors using 2-aryl-naphthyridin-4-ones |
| 684 |
6,069,146 |
|
Halimide,
a cytotoxic marine natural product, and derivatives thereof |
| 685 |
6,066,749 |
|
Method
for conversion of C-2'-O-protected-10-hydroxy taxol to
c-2'-O-protected taxol:useful intermediates in paclitaxel synthesis |
| 686 |
6,066,748 |
|
Process
of extracting TAXOL.RTM. from taxus cuspidata |
| 687 |
6,066,668 |
|
Formulations
and methods of reducing toxicity of antineoplastic agents |
| 688 |
6,066,645 |
|
Formulations
and methods of reducing toxicity of antineoplastic agents |
| 689 |
6,066,635 |
|
Avrainvillamide,
a cytotoxic marine natural product, and derivatives thereof |
| 690 |
6,063,780 |
|
Method
of treating a tumor |
| 691 |
6,060,083 |
|
Topical
DMSO treatment for palmar-plantar erythrodysethesia |
| 692 |
6,057,361 |
|
Formulations
and methods of reducing toxicity of antineoplastic agents |
| 693 |
6,057,359 |
|
Spontaneously
dispersible concentrates comprising esters of baccatin-III compounds
having antitumor and antiviral activity |
| 694 |
6,054,492 |
|
Fluorinated
copolymeric pharmaceutical adjuncts |
| 695 |
6,054,444 |
|
Phosphonic
acid derivatives |
| 696 |
6,054,122 |
|
Supplemented
and unsupplemented tissue sealants, methods of their production and
use |
| 697 |
6,051,600 |
|
Liposomal
hydrolysis-promoting hydrophobic taxane derivatives |
| 698 |
6,051,563 |
|
Methods
for the administration of amifostine and related compounds |
| 699 |
6,048,990 |
|
Method
for selective acylation of C-2'-O-protected-10-hydroxy-taxol at the
C-10 position |
| 700 |
6,048,849 |
|
Formulations
and methods of reducing toxicity of antineoplastic agents |
No. 1
- 100 / 101-200
/ 201 - 300 / 301
- 400 / 401 - 500
/ 501 - 600 / 601
- 700 / 701 - 800
/ 801
- 900 / 901 -939
/
|
